Developing a Patient-Centered Counseling Tool for Resuming Sexual Activity After Pelvic Reconstructive Surgery: A Qualitative and Cognitive Interview Approach
Posted inOB/GYN & Women's Health Plastic Surgery Urology

Developing a Patient-Centered Counseling Tool for Resuming Sexual Activity After Pelvic Reconstructive Surgery: A Qualitative and Cognitive Interview Approach

A novel, evidence-based counseling tool was developed to guide patients in safely resuming sexual activity after pelvic reconstructive surgery. The tool integrates patient perspectives and expert input, addressing safety, discomfort, and recovery expectations.
Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis
Posted inClinical Updates news Oncology Urology

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients ineligible for cisplatin, with manageable safety.
Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
Posted innews Oncology Urology

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.